UCL offers cutting-edge MSc in Nanotechnology and Regenerative Medicine

1 June 2009

UCL is offering a cutting-edge course in the rapidly expanding field of nanotechnology and regenerative medicine.

nanotech

The MSc in Nanotechnology and Regenerative Medicine will give students a robust scientific understanding and equip them with research and transferable tools.

The course, based within UCL’s Division of Surgery and Interventional Science, includes mandatory modules on nanotechnology, stem cells technology and tissue engineering.

It also features a hands-on module in molecular and bionanotechnology techniques and a workshop-based module in statistics in biomedical research.

A laboratory-based research project is a fundamental part of the course and opens up opportunities for further research and possible publications.

The course is designed to be accessible to students from a range of disciplines, including medicine, biology, physics, chemistry, engineering and other science subjects.

Course leader Professor Alexander Seifalian said: “When we were designing this course,  we looked at what was on offer at other universities in the UK and Europe and, to our knowledge, this is the first that focuses on nanotechnology as applied to regenerative medicine. There’s nothing else like it. The course is 50% taught and 50% cutting-edge research. It is ideal for students who want to follow it up with a PhD or get a job in academia or industry.”

The MSc course, which starts in September 2009, lasts one year full-time or two years part-time.

For more information contact Professor Seifalian.

Image: a researcher performs a nanotechnology experiment.

 

UCL context

The Division of Surgery and Interventional Science is part of the most prestigious medical schools in Europe, with a team of nearly 400 people, from surgeons and oncologists to clinical trials specialists and researchers.

Related stories:

UCL–Pfizer to develop pioneering stem cell sight therapies

£5million for nanotechnology healthcare research

US stem cell funding ban lift: the implications